



# Medicines & Healthcare products Regulatory Agency

## MHRA Freedom of Information Act (FOIA) request Disclosure Log index

This document contains reference details for all FOIA requests which have been answered in full or in part, or for which the agency held no information.

It is a fully searchable PDF which will produce a list of all requests containing the chosen search term.

If you wish to see the original request and subsequent agency reply, please send an email headed "Disclosure Log request" to:

[FOI\\_policy@mhra.gsi.gov.uk](mailto:FOI_policy@mhra.gsi.gov.uk)

As long as it is headed correctly it will not be treated as a new FOIA request. The identity of the original requester will be redacted.

**Updated: 1 June 2017**

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/063	Request for Disclosure of Documents: Copaxone	02/03/2017	Disclosed in part
17/064	Information relating to Fixed Telecommunications and Internet Services	09/03/2017	Disclosed in full
17/065	Information related to the safety/side effects/toxicity of halothane, and anaesthetic	13/03/2017	Disclosed in full
17/068	Information request relating to the Organisation's existing contracts relating to facilities management.	15/03/2017	Disclosed in full
17/069	Variation details for licence (Lariam/Mefloquine)	15/03/2017	Disclosed in full
17/070	Side effects, licensing information on numerous products	07/03/2017	Disclosed in part
17/071	Referrals process between the MHRA and the PMCPA	14/03/2017	Disclosed in full
17/072	please provide all consideration within MHRA of the recent publication: Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase	20/03/2017	Disclosed in full
17/073	Information about the organisations information technology team and infrastructure equipment	02/03/2017	Disclosed in full
17/076	Provide the last 15 inspection reports for signal detection	21/03/2017	Disclosed in part
17/078	Legal basis for MA of Deep Relief 5%/3% gel, PL 00189/0027 and the finished product specification at release and shelf-life.	02/03/2017	Disclosed in part
17/079	Clinical information on Hydroxocobalamin	22/03/2017	Disclosed in part
17/080	Pharmacokinetic characteristics of Azzalure (Reloxin, Dysport)	15/03/2017	Disclosed in part
17/081	Contract award made by your organisation	21/03/2017	Disclosed in part
17/082	List of CROs (Contract Research Organisations)	16/03/2017	Disclosed in full
17/083	Clinical trials/research in endometriosis	21/03/2017	Disclosed in part
17/084	GMP audit metrics	24/03/2017	Disclosed in part
17/085	Provide me with the information about total number of FIH CTAs that have been submitted for last five years (2011-2016) to MHRA	24/03/2017	Disclosed in full
17/088	Information about clinical trials Prostag	28/03/2017	Disclosed in part
17/090	Iron therapy for female athletes	22/03/2017	Disclosed in part
17/092	Audit report for Almac Sciences Limited	03/04/2017	Disclosed in part
17/094	Product information on Deep Relief 5%/3% gel, PL 00189/0027	03/04/2017	Disclosed in part
17/096	Drug Print Out of all adverse reactions for the HPV vaccination reported between 1st September 2008 and the current date	31/03/2017	Disclosed in full
17/097	Procurement and usage of vehicle ownership, lease or rental	24/03/2017	Disclosed in full
17/100	Procurement and usage of vehicle ownership, lease or rental for British Pharmacopeia	24/03/2017	Disclosed in full
17/101	Follow up to FOI 15/545 on yellow card reports	24/03/2017	Disclosed in full
17/104	Inspection reports of the Western Isles Blood Transfusion service carried out in 2015, 2016 and 2017	07/04/2017	Disclosed in part
17/105	Reports cases relating to HPV vaccinations, NHS vaccination or any other vaccines given	10/04/2017	Disclosed in full
17/106	Explanation why Primodos was contraindicated as a pregnancy test in 1974 on the internal patient information leaflet in the box of Primodos	15/03/2017	Disclosed in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/107	Number of complaints against the PV Inspectorate	24/03/2017	Disclosed in full
17/108	(PSUR) and risk management plans (RMP) for Bisoprolol Tablets	30/03/2017	Disclosed in full
17/112	Side effects of Isotretinoin	10/04/2017	Disclosed in full
17/113	Indication of your current IT budget and which IT systems you use to support and manage inspections? Also can you please confirm the number of inspectors and the number of inspections a year?	12/04/2017	Disclosed in full
17/114	New medical devices registered in the UK each year	31/03/2017	Disclosed in full
17/115	Information on various products (Adderall, Methylphenidate, 23andMe)	07/04/2017	Disclosed in full
17/116	RMP for Duraphat 5000 ppm Fluoride Toothpaste	21/03/2017	Disclosed in full
17/118	Toxicity of HPV Vaccines	28/03/2017	Disclosed in part
17/119	Current and expired scientific opinions completed within 75, 90 day procedures	20/04/2017	Disclosed in full
17/120	RMP for Flouride 2800 & 5000PPM toothpaste	24/03/2017	Disclosed in part
17/121	Adverse vaccine reactions from MMR vaccine over the last 10 years, from 2007	18/04/2017	Disclosed in full
17/122	Can you tell me how many documents were exempted under commercial sensitivity?	27/03/2017	Disclosed in full
17/124	Can you tell me how the MHRA decides when a drug has enough adverse reactions to warrant that drug being investigated? Can I have a copy of all PILs issued since 2004 for Citalopram and paroxetine	21/04/2017	Disclosed in full
17/125	Information on CVs received by MHRA	20/04/2017	Disclosed in part
17/128	Number of MRI burns in patients and incidents reported	24/04/2017	Disclosed in part
17/130	Information on problems reported in the UK with SERI scaffold knitted silk implant	31/03/2017	Disclosed in part
17/131	Drug Analysis Prints (DAP's) for Fluenz and separately for Fluenz Tetra	26/04/2017	Disclosed in full
17/132	RMP for Bisoprolol 10mg Tablets – Noumed life sciences limited. PL 44041/005	25/04/2017	Disclosed in part
17/134	Information about prostrap & endometriosis	28/04/2017	Disclosed in full
17/136	Documents received from Berlin archives - Primodos	08/05/2017	Disclosed in part
17/137	Questions relating to PIP Implants	25/04/2017	Disclosed in full
17/139	Qualitative and Quantitative composition - Voltarol	19/04/2017	Disclosed in part
17/141	Adverse reaction data (2015/2016) medicines and devices	11/05/2017	Disclosed in full
17/142	2016 ADR data including outcomes	12/05/2017	Disclosed in full
17/144	Request for safety assessment reports	11/05/2017	Disclosed in full
17/146	Roche documents relating to Lariam (mefloquine)	02/05/2017	Disclosed in part
17/147	MA Dossier for DUAC PL 19494/0075 & ERA UK/H/0676/002DC	17/05/2017	Disclosed in part
17/148	Complaints/adverse events within the bordered foams categories	12/05/2017	Disclosed in full
17/149	Number of adverse incident reports you have received via the MHRA's yellow card scheme or other reports, regarding problems with contact lenses, and specifically, contact lens related infections	16/05/2017	Disclosed in full
17/150	Information about TPD	05/05/2017	Disclosed in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/151	SPC for Hypertensin® (angiotensin II amide)	11/05/2017	Disclosed in full
17/152	Information on Homicide SSRIS	19/05/2017	Disclosed in full
17/155	The safety and efficacy evidence that supports the marketing authorisation for Actavis' Amitriptyline 10 mg, 25mg and 50 mg tablets, (2) the date of Actavis' application, and (3) the date of the authorisation.	17/05/2017	Disclosed in full
17/159	Telephone Maintenance Information	23/05/2017	Disclosed in part
17/160	Availability for several PARs Potassium Chloride products	25/04/2017	Disclosed in part
17/163	Will the MHRA please confirm the figure of babies affected by Sodium Valproate prescribed during pregnancy between the dates of February 2016 to February 2017	26/05/2017	Disclosed in full
17/167	a) please provide me with a copy of the advice sent to DeepMind on May 11 b) has the MHRA made a determination about whether DeepMind's deployment of Streams at the Royal Free in late 2015 and early 2016 constituted "bringing a product to market". If so, please provide me with a copy of that determination	25/05/2017	Disclosed in full
17/168	Side effects of isotretinoin	26/05/2017	Disclosed in part
17/170	Adverse sexual effects caused by SSR	24/05/2017	Disclosed in full
17/171	RMP for Ezterol	26/05/2017	Disclosed in part
17/174	Side effects of taking Isotretinoin	26/05/2017	Disclosed in part
17/176	ADRs botulinum toxin type A (Dysport/Azzalure)	25/05/2017	Disclosed in full
17/177	ingrediance for sertralinetablets UKPAR 50mg& 100mg	08/05/2017	Disclosed in full
17/178	CT report Buttercup Bronchostop Cough Syrup	31/05/2017	Disclosed in part
17/187	questions regarding the product called Azzalure	25/05/2017	Disclosed in full
17/188	MHRA structure	18/05/2017	Disclosed in full
17/195	Can you confirm that DeepMind has all the required approvals to have deployed Streams at the Royal Free?	26/05/2017	Disclosed in full